Skip to main content
Home > SciBX on Science > Translational Notes

Chronological Index of SciBX: The Science-Business eXchange: Translational Notes

SciBX: The Science-Business eXchange Current Issue
  • Proximity matters

    Recent translational deals by sanofi-aventis and Roche provide a glimpse into how the pharma companies are rolling out their global efforts to access early-stage research.

    Published on 6/17/2010
  • Filling the gap

    With £9.6 million in hand, U.K.-based drug development company TPP Global Development is now ready to start scouring the academic space for early-stage science it wants to translate into commercial-ready assets.

    Published on 6/3/2010
  • Cisalpine translation

    The Italian Institute of Technology wants to jump-start scientific entrepreneurship in Italy by creating a new drug discovery center that will occupy the preclinical development space traditionally held by venture-…

    Published on 4/15/2010
  • Table: Tuberculosis pipeline

    Translational Notes: Combining against tuberculosis Table 1. Tuberculosis pipeline. Clinical-stage compounds for treating tuberculosis. Source: BCIQ: BioCentury Online Intelligence; Working Group on New TB Drugs …

    Published on 4/8/2010
  • Combining against tuberculosis

    Drawing on lessons learned from the fight against HIV, the Global Alliance for TB Drug Development has partnered with the Critical Path Institute to map out a strategy for testing combinations of new classes of …

    Published on 4/8/2010
  • Translational triumvirate

    A joint venture between Southern Research Institute, the University of Alabama at Birmingham and India's Jubilant Organosys aims to streamline development of therapeutics for cancer, infectious disease and metabolic …

    Published on 12/10/2009
  • Table 1: Getting Started

    Science for Export Table 1. Getting started. Selected list of companies that Emory University, Institut National de la Santé et de la Recherche Médicale (INSERM), Max Planck Innovation GmbH, Northwestern University, …

    Published on 6/25/2009
  • Science for export

    Although every major university or institute would like to be located in a biotech hub and keep its discoveries close to home, only a few true hubs exist. For everyone else, the question is whether their research will …

    Published on 6/25/2009
  • Table 1

    Translational Notes: Stand Up Act Table 1. Stand Up To Cancer awards. The charity will pay out $73.6 million over 3 years to 5 groups of cancer researchers. Team leaders Research focus Grant ($M) Craig Thompson, …

    Published on 6/4/2009
  • Stand Up act

    Stand Up To Cancer has awarded the first round of funds raised during its 2008 charity drive, directing the $73.6 million to 5 teams of cancer researchers whose projects could enter the clinic within 3 years.

    Published on 6/4/2009
  • Fast Forward in MS

    EMD Serono has partnered with the venture philanthropy organization Fast Forward to advance MS research in the translational space. Backed by the National Multiple Sclerosis Society, the deal could accelerate …

    Published on 5/28/2009
  • Max Planck ripens its fruit

    Faced with dwindling corporate and investor interest in early-stage IP, the Max Planck Society is collaborating with Life Science Partners to set up a venture arm to finance the development of promising projects until …

    Published on 5/21/2009
  • Genomewide vs. genome dive

    Although a New England Journal of Medicine commentary argues for a shift in resources away from genomewide association studies and toward deep sequencing of particular individuals to understand the highest-impact …

    Published on 4/23/2009

< Previous   1  2  3  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

SciBX: Science-Business eXchange

BioCentury's weekly translational science journal, published in collaboration with Nature Publishing Group:

  • Selects from hundreds of scientific papers published each week to identify early opportunities for investment, alliances and partnerships
  • Reports on the most commercially relevant developments